A citation-based method for searching scientific literature

G Ploussard, C Hennequin, F Rozet. Cancer Radiother 2017
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Leonard P Bokhorst, Riccardo Valdagni, Antti Rannikko, Yoshiyuki Kakehi, Tom Pickles, Chris H Bangma, Monique J Roobol. Eur Urol 2016
159
100

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Rodrigo R Pessoa, Publio C Viana, Romulo L Mattedi, Giuliano B Guglielmetti, Mauricio D Cordeiro, Rafael F Coelho, William C Nahas, Miguel Srougi. BJU Int 2017
26
100

Medium-term outcomes of active surveillance for localised prostate cancer.
Elizabeth D Selvadurai, Mausam Singhera, Karen Thomas, Kabir Mohammed, Ruth Woode-Amissah, Alan Horwich, Robert A Huddart, David P Dearnaley, Chris C Parker. Eur Urol 2013
142
100

Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.
Lars Holmberg, Anna Bill-Axelson, Gunnar Steineck, Hans Garmo, Juni Palmgren, Eva Johansson, Hans-Olov Adami, Jan-Erik Johansson. J Natl Cancer Inst Monogr 2012
24
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100

Screening and prostate-cancer mortality in a randomized European study.
Fritz H Schröder, Jonas Hugosson, Monique J Roobol, Teuvo L J Tammela, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Hans Lilja, Marco Zappa,[...]. N Engl J Med 2009
100

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Rebecka Arnsrud Godtman, Erik Holmberg, Ali Khatami, Carl-Gustaf Pihl, Johan Stranne, Jonas Hugosson. Eur Urol 2016
74
100

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
Mieke Van Hemelrijck, Xi Ji, Jozien Helleman, Monique J Roobol, Wim van der Linden, Daan Nieboer, Chris H Bangma, Mark Frydenberg, Antti Rannikko, Lui S Lee,[...]. Eur Urol 2019
18
100

[Oncological results of active surveillance in prostate cancer: A retrospective multicentric cohort].
P Mortier, C Bastide, E Lechevallier, J Walz, R Fournier, P-H Savoie, K Ben Othman, R Giorgi, M André, S Giusiano,[...]. Prog Urol 2017
2
100

Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.
Seyed Saeid Dianat, H Ballentine Carter, Kenneth J Pienta, Edward M Schaeffer, Patricia K Landis, Jonathan I Epstein, Bruce J Trock, Katarzyna J Macura. Urology 2015
38
100

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Theodor van der Kwast, Malcolm Mason, Vsevolod Matveev, Thomas Wiegel, F Zattoni,[...]. Eur Urol 2014
100

[CCAFU Recommendations 2013: Prostate cancer].
L Salomon, C Bastide, P Beuzeboc, L Cormier, G Fromont, C Hennequin, P Mongiat-Artus, M Peyromaure, G Ploussard, R Renard-Penna,[...]. Prog Urol 2013
55
100

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Timo F W Soeterik, Harm H E van Melick, Lea M Dijksman, Douwe H Biesma, J Alfred Witjes, Jean-Paul A van Basten. Eur Urol Oncol 2018
3
100


Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
Andrew J Simpkin, Kate Tilling, Richard M Martin, J Athene Lane, Freddie C Hamdy, Lars Holmberg, David E Neal, Chris Metcalfe, Jenny L Donovan. Eur Urol 2015
66
100

A multi-institutional evaluation of active surveillance for low risk prostate cancer.
Scott E Eggener, Alex Mueller, Ryan K Berglund, Raj Ayyathurai, Cindy Soloway, Mark S Soloway, Robert Abouassaly, Eric A Klein, Steven J Jones, Chris Zappavigna,[...]. J Urol 2009
72
100

Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.
Maria Komisarenko, Narhari Timilshina, Patrick O Richard, Shabbir M H Alibhai, Robert Hamilton, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner, Antonio Finelli. J Urol 2016
17
100

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.
Hebert Alberto Vargas, Oguz Akin, Asim Afaq, Debra Goldman, Junting Zheng, Chaya S Moskowitz, Amita Shukla-Dave, James Eastham, Peter Scardino, Hedvig Hricak. J Urol 2012
159
100

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Freddie C Hamdy, Jenny L Donovan, J Athene Lane, Malcolm Mason, Chris Metcalfe, Peter Holding, Michael Davis, Tim J Peters, Emma L Turner, Richard M Martin,[...]. N Engl J Med 2016
100

Active surveillance in patients with a PSA >10 ng/mL.
Paul Toren, Lih-Ming Wong, Narhari Timilshina, Shabbir Alibhai, John Trachtenberg, Neil Fleshner, Antonio Finelli. Can Urol Assoc J 2014
8
100

Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance.
Bong H Park, Hwang G Jeon, Seol H Choo, Byong C Jeong, Seong I Seo, Seong S Jeon, Han Y Choi, Hyun M Lee. BJU Int 2014
67
100

Radical prostatectomy versus watchful waiting in early prostate cancer.
Anna Bill-Axelson, Lars Holmberg, Mirja Ruutu, Hans Garmo, Jennifer R Stark, Christer Busch, Stig Nordling, Michael Häggman, Swen-Olof Andersson, Stefan Bratell,[...]. N Engl J Med 2011
536
100

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.
Jeffrey J Tosoian, Mufaddal Mamawala, Jonathan I Epstein, Patricia Landis, Sacha Wolf, Bruce J Trock, H Ballentine Carter. J Clin Oncol 2015
296
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.